中药行业周报：医保政策激活基层市场，中药及慢病用药迎扩容机遇-20260322

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The report highlights that the recent healthcare policies are expected to activate the grassroots market, providing expansion opportunities for traditional Chinese medicine (TCM) and chronic disease medications [2][12] - The TCM sector is anticipated to benefit from the government's support for grassroots healthcare services, which aims to enhance accessibility and affordability for patients [8][12] - The report emphasizes the importance of policy developments, particularly the "14th Five-Year Plan" for TCM, which focuses on value-driven growth and innovation [12] Market Performance - The TCM sector experienced a decline of 1.16% last week, which was the smallest drop among the pharmaceutical sub-sectors [4][20] - The overall pharmaceutical sector saw a decline of 2.77% during the same period [4][20] - The TCM sector's price-to-earnings (PE) ratio (ttm) is reported at 26.35X, with a decrease of 0.25X week-on-week, while the price-to-book (PB) ratio (lf) stands at 2.21X, down 0.03X [6] Company Performance - Top-performing companies in the TCM sector include Dong'e Ejiao, China Resources Sanjiu, Jichuan Pharmaceutical, Lingrui Pharmaceutical, and Panlong Pharmaceutical [5] - Underperforming companies include Changyao Tui, Weikang Pharmaceutical, Yibai Pharmaceutical, Zhenbaodao, and ST Bailing [5] Valuation - The TCM sector's PE ratio is at 26.35X, which is within the 26.13% percentile since 2013, while the PB ratio is at 2.21X, within the 4.07% percentile since 2013 [6] Raw Material Market - The market for TCM raw materials is strengthening, with the price index rising by 1.1% last week, indicating a favorable trend for the sector [7] Policy Support - The recent guidance from the National Healthcare Security Administration aims to enhance grassroots healthcare services, which is expected to drive demand for TCM and chronic disease medications [8][12] - Specific measures include increasing the allocation of healthcare funds to grassroots services and improving payment systems to support chronic disease management [8][12] Investment Recommendations - The report suggests focusing on companies with strong evidence of clinical efficacy, research and development capabilities, quality control advantages, and brand strength [13] - Key recommendations include Yiling Pharmaceutical and Zuoli Pharmaceutical, with a watch on the recovery of consumer demand for TCM products [13]